Duncker Streett & Co. Inc. Sells 200 Shares of Elevance Health, Inc. (NYSE:ELV)

Duncker Streett & Co. Inc. lowered its position in shares of Elevance Health, Inc. (NYSE:ELV) by 2.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 7,492 shares of the company’s stock after selling 200 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Elevance Health were worth $3,533,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Fortis Capital Advisors LLC purchased a new position in Elevance Health in the 4th quarter worth about $29,000. TD Capital Management LLC bought a new stake in shares of Elevance Health in the fourth quarter worth approximately $30,000. OFI Invest Asset Management purchased a new position in shares of Elevance Health during the third quarter valued at approximately $25,000. Householder Group Estate & Retirement Specialist LLC bought a new position in Elevance Health during the third quarter valued at approximately $30,000. Finally, ORG Partners LLC purchased a new stake in Elevance Health in the fourth quarter worth approximately $40,000. 89.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ELV has been the topic of several research analyst reports. Wells Fargo & Company lowered their price target on Elevance Health from $561.00 to $557.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Royal Bank of Canada upped their price objective on Elevance Health from $572.00 to $574.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Barclays started coverage on Elevance Health in a research report on Wednesday, March 6th. They issued an “overweight” rating and a $584.00 target price on the stock. StockNews.com cut shares of Elevance Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $580.00 target price on shares of Elevance Health in a research report on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $569.00.

Elevance Health Trading Up 1.4 %

ELV traded up $6.88 on Wednesday, hitting $506.97. The company had a trading volume of 1,127,280 shares, compared to its average volume of 854,056. The business’s fifty day simple moving average is $507.94 and its 200 day simple moving average is $482.10. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.59. Elevance Health, Inc. has a 12-month low of $412.00 and a 12-month high of $521.18. The company has a market cap of $117.97 billion, a PE ratio of 20.14, a PEG ratio of 1.10 and a beta of 0.78.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 24th. The company reported $5.62 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.02. Elevance Health had a net margin of 3.49% and a return on equity of 20.47%. The business had revenue of $42.45 billion for the quarter, compared to the consensus estimate of $42.19 billion. During the same quarter in the prior year, the firm posted $5.23 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts expect that Elevance Health, Inc. will post 37.03 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Friday, March 8th were issued a $1.63 dividend. This represents a $6.52 annualized dividend and a dividend yield of 1.29%. This is an increase from Elevance Health’s previous quarterly dividend of $1.48. The ex-dividend date of this dividend was Thursday, March 7th. Elevance Health’s dividend payout ratio is presently 25.90%.

Insider Buying and Selling

In other news, Director Ramiro G. Peru sold 753 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total transaction of $376,500.00. Following the completion of the sale, the director now directly owns 9,109 shares of the company’s stock, valued at $4,554,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.29% of the stock is owned by corporate insiders.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.